GRI Bio (GRI) EBIT (QoQ) (2020 - 2026)
GRI Bio (GRI) EBIT (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - |
| 10 | GRI Bio | 3.02 Mn | 3.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.81% |
| Dec 31, 2025 | 20.83% |
| Sep 30, 2025 | -16.15% |
| Jun 30, 2025 | 5.05% |
| Mar 31, 2025 | -56.14% |
| Dec 31, 2024 | 8.26% |
| Sep 30, 2024 | 5.63% |
| Jun 30, 2024 | -19.10% |
| Mar 31, 2024 | 6.47% |
| Dec 31, 2023 | 16.93% |
| Sep 30, 2023 | 58.90% |
| Jun 30, 2023 | -500.61% |
| Mar 31, 2023 | 40.73% |
| Dec 31, 2022 | -796.24% |
| Sep 30, 2022 | 1.59% |
| Jun 30, 2022 | 92.82% |
| Mar 31, 2022 | 14.87% |
| Dec 31, 2021 | -146.93% |
| Sep 30, 2021 | 45.76% |
| Jun 30, 2021 | 11.22% |